fda semaglutide shortage status january 2025 GLP-1 = Over FDA Declares Shortage of Novo

( Brunetti et al

Q3: Are the Ipamorelin benefits for men permanent

Oncolytic virotherapy for cancer: clinical experience

Functional cereal products in the diet for type 2 diabetes patients

NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP-1 Weight Loss Drugs Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 Washington, DC A year ago, the National Consumers League took the unusual step of flagging warnings from the Food and Drug Administration (FDA) and medical societies stating that compounded versions of GLP-1 (glucagon-like peptide-1 receptor agonists) weight-loss drugs are not FDA approved and may cause serious health problems